Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PatentHEALTH appeals NAD decision

This article was originally published in The Tan Sheet

Executive Summary

The Canton, Ohio-based firm appeals the National Advertising Division's recommendation to discontinue claims that the Trigosamine Fast Acting joint-health supplement provides "rapid relief." The study PatentHEALTH relies on to make the claims found participants walked farther after taking Trigosamine FA for three days than those taking a placebo. The advertising watchdog said the study was insufficient evidence. PatentHEALTH agreed to discontinue the claim, but will appeal NAD's interpretation of the study to CBBB's National Advertising Review Board. It also will appeal NAD's recommendation to make advertorials look more like ads and less like news articles. NAD recommended the firm not compare its supplement to a competing product based on study-to-study comparisons because there are too many uncontrolled variables between the studies, according to a July 9 NAD report. Nutramax Laboratories challenged PatentHEALTH's claim, NAD said

Related Content

NARB panel confirms recommendations to PatentHEALTH





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts